Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.

Tomohiro ShimizuKosuke AritaEihiro MurotaShigeto HiratsukaRyo FujitaHotaka IshizuTsuyoshi AsanoDaisuke TakahashiMasahiko TakahataNorimasa Iwasaki

Published in: Journal of bone and mineral metabolism (2021)

ROMO continuously increased BMD for 12 months and performed better than DENO. On the other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were almost same with DENO. Bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months may predict the efficacy of ROMO after 12 months of administration.

Keyphrases

total hip
bone mineral density
total knee arthroplasty
end stage renal disease
ejection fraction
postmenopausal women
prognostic factors
peritoneal dialysis
body composition
patient reported